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The collaboration 
Full details of the Premenopausal Breast Cancer Collaborative Group have been published elsewhere.1 Individual-level 
data were pooled from 19 prospective cohorts with 100 breast cancer cases diagnosed before age 55 years, with the 
collaboration facilitated by the National Cancer Institute Cohort Consortium. Data were harmonised to a common 
template for 1-16 questionnaire rounds per study; all studies had at least two rounds except for the European Prospective 
Investigation into Cancer and Nutrition (EPIC) study, the Canadian Study of Diet, Lifestyle and Health (CSDLH), and 
HUNT2 for which only the baseline questionnaire was available. One study (CSDLH) provided data for a case-cohort 
subset; all the others provided data for the full cohort. Seventeen studies provided information on incident invasive and 
in-situ breast cancer and two (HUNT2 and Canadian Study of Diet, Lifestyle, and Health, CLDLH) on invasive breast 
cancer only. The pooled dataset was used to construct a dataset to investigate the endpoint of premenopausal breast 
cancer. 
 
Derivation of age at menopause and premenopausal follow-up time 
 
All cohorts collected information on menopausal status of participants at one or more questionnaire rounds. Participants 
were asked whether they had had any menstrual periods during the previous 6 or 12 months, depending on study, and/or 
whether they believed their periods had stopped permanently. Participants were asked about the age at their last period 
and the reason their periods stopped. We used this information to construct premenopausal follow-up time for analysis. 
Age at menopause was computed for each participant based on (i) reported age at menopause or, if age was missing, (ii) 
age first known postmenopausal if under age 50, (iii)  age last known premenopausal if over age 50 or (iv) age 50 if no 
information was provided. When a hysterectomy was reported as reason for the menopause follow-up was censored at 
the reported age of the procedure. Since women with breast cancer often become postmenopausal due to their treatment 
and breast cancers diagnosed in the year of their menopause could be considered aetiologically premenopausal, we 
lagged reported menopausal ages (subjects under i) for all women by +1 year, i.e. the year during which they reported 
that they had become postmenopausal was analysed as premenopausal follow-up time. As a sensitivity analysis, we 
repeated the main analyses including only known premenopausal follow-up time up to the age at reported menopause 
(subjects under i) or, if age at menopause was missing, the age at the last questionnaire when the participant reported she 
was premenopausal (ii and iii).  
 
Computation of BMI at various ages 
We used data on current weight at the time of questionnaire completion and on recalled weight at ages before 
questionnaire completion, to construct variables for weight within the age ranges 18-24, 25-34, 35-44, 45-54 years. None 
of the studies had information to calculate BMI at ages younger than 18 years. Most weights at ages 18-24 years were 
retrospectively reported (most often for ages 18-21) but a minority were concurrently reported by subjects who were 
recruited at ages 18-24 years. At ages 25-34, 35-44 and 45-54, the majority of weights were concurrently reported. 
When weights were assessed on multiple occasions within an age category we used the earliest concurrent weight or 
otherwise the retrospectively reported weight relative to the youngest age within the age group. We recoded the 
following extreme values to missing based on visual inspection of histograms and percentile distributions: height (<130 
or >195 cm), weight (<30, >200 kg), BMI (<15, >49 kg/m2) and weights that arose from BMI values outside this range. 
In pooled analyses, BMI was categorised according to World Health Organization definitions2 as severe/moderate 
thinness (<17 kg/m2), mild thinness (17-18.5 kg/m2), normal range (18.5-22.9 and 23.0-24.9 kg/m2), overweight (25-
27.4 and 27.5-29.9 kg/m2), obese Class I (30-32.4 and 32.5-34.9 kg/m2) and obese Class II/III  (35 kg/m2). Where 
numbers in the extreme categories were small or to obtain study-specific, stratum-specific or tumor type-specific 
estimates we combined categories to obtain stable estimates. For each age-specific BMI investigated, studies with less 
than 10 cases among subjects with known BMI were excluded from the model to improve convergence. 
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Clinicopathological surrogate definition of breast cancer intrinsic subtypes 
Immunohistochemistry data on estrogen (ER) and progesterone receptor (PR) status, as well as data on Human 
epidermal growth factor receptor-2 (HER2) oncogene expression was collected from the centres. Given the absence of 
data on the proliferation marker KI-67, we adapted clinicopathological surrogate definitions of luminal A and luminal B-
like intrinsic breast cancer subtypes proposed by the St Gallen Expert Consensus.3 We classified all ER+PR+HER2- 
breast cancer as luminal A-like, ER+PR-HER2- and ER-PR+HER2- as luminal B-like HER2 negative, 
[ER+/PR+]HER2+ to luminal B-like HER2 positive, ER+PR- and ER-PR+ with HER2 status unknown as luminal B 
unclassified, ER+ or PR+ with other markers unknown as unclassified luminal, ER-PR-HER2- as triple-negative, ER-
PR-HER2+ as HER2 enriched, ER- with PR unknown or PR- with ER unknown regardless of HER2 status as 
unclassified.   
 
Statistical methods 
Analyses were conducted using Stata 14.2 software4. BMI was analysed separately as a categorical and as a continuous 
variable (per 5 kg/m2), assuming a log-linear dose-response relationship, the validity of which was checked using 5-knot 
restricted cubic spline models.5 Hazard ratios (HR) as estimates of relative risk of breast cancer were obtained from Cox 
proportional hazards models6 with attained age as the underlying time-scale. All analyses were conducted using Stata 
14.2 software4. Pooled analyses were adjusted for attained age (implicit in the Cox model) and cohort (including country 
within EPIC). In multivariable-adjusted models we additionally adjusted for year of birth (<1930, 1930-9, 1940-9, 1950-
9, 1960-9, 1970-9,  to 1980), age at menarche (7-11, 12-13, 14 years, not known), age at first birth (<25, 25-34, 35 
years,  not known or not applicable), time since last birth (<5, 5-9, 10-14, 15-19, 20-24, 25-29, 30 years, not known or 
not applicable), parity (0, 1, 2, 3, parous but not known) and family history of breast cancer (yes, no, not known). 
Hazard ratios for breast cancer with respect to BMI were near-identical in age- and cohort-adjusted models compared 
with models additionally (fully) adjusted for other breast cancer risk factors. Fully adjusted models are therefore 
presented in the main paper. In models additionally adjusted for BMI at age 18-24, BMI at this age was coded as <18.5, 
18.5-22.9, 23.0-24.9, 25.0-27.4, 27.5-29.9, 30 kg/m2). Height was included as a continuous variable in models 
additionally adjusted for adult height. Covariate information was time-updated, where possible, with information from 
follow-up questionnaires for all pregnancy-related variables and family history of breast cancer. Subjects with missing 
covariate values were included in the analyses by fitting a category for the missing value.  
In order to include the case-cohort study (CSDLH) in the pooled data set, we included Barlow weights7 for CSDLH 
corresponding to a sampling fraction of 5.0 percent as an off-set in the model. We also applied Barlow weights with a 
sampling fraction of (effectively) 1.0 to all other cohorts using the stcasecoh command in Stata 14.2 software4, which 




In sensitivity analyses, we repeated the analyses (i) for BMI at ages 25 onwards adjusting for BMI at age 18-24 years 
(Figure 1) (ii) for BMI at ages 25 onwards restricted to individuals for whom BMI at ages 18-24 was also available 
(eTable 2)  (iii) excluding subjects whose weight was recalled or reported less than three years postpartum  (eTable 7) 
(iv) restricting follow-up to person-time that was known to be, rather than assumed to be, premenopausal (eTable 7) (v) 
excluding the first two years of follow-up (eTable 7) (vi) restricting the endpoint to breast cancer with information on all 
of ER, PR and HER2 status (eTable 7) (vii) excluding one cohort at the time (eTable 8) (viii) additional adjustment for 
adult height (not shown) (vix) comparing with and without adjustment for polycystic ovary syndrome (PCOS), for 
centres with data on PCOS (not shown). 
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eTable 1: Study characteristics and numbers of premenopausal women with information on BMI, by cohort study  

















BMI age 18-24 
years 
BMI age 25-34 
years 
BMI age 35-44 
years 






















BWHS USA 45091 35.2 20.4 12 828 20.9 44482 25.3 21447 27.1 35361 28.4 25553 




1105 42.5 23.1 6.4 213 20.5 1099 22 156 22.9 552 23.2 381 
CTS USA 45708 41.2 22.2 8.8 641 20.8 45327 22.3 12107 23 23370 23.6 18184 
E3N France 58215 44.7 38.6 6.4 1245 - 0 (c) - 0 (c) 21.4 30674 22 54722 
EPIC (b) Europe 94967 40.8 19.9 8.2 942 21.1 49045 22.2 15535 23.7 47837 24.8 27553 
GS UK 60916 38.4 18 6.4 655 21.6 59751 22.7 34825 23.8 47284 24.5 23865 
HUNT2 Norway 16889 36.5 20.5 12 117 23.5 2090 24.1 5282 24.5 6423 25.3 3094 
MCC Australia 8097 45.4 31.1 4.6 86 20.8 7985 - 0 (c) 24.2 3720 24.9 6448 
NHS USA 94945 40.6 29.5 13.4 2334 20.9 76550 21.9 21372 22.5 65826 23.8 88173 
NHS2 USA 83620 36.8 24.8 14.2 2515 20.6 82703 22.4 28926 23.2 82528 25.1 68850 
NOWAC Norway 75740 42.5 31.5 6.5 797 20.4 72012 22 3991 22.3 45472 23.5 44139 
NYUWHS USA 6649 43.5 31.5 7.5 241 - 0 (c) 22.1 85 22.9 4259 23.9 4544 
RERF Japan 11430 40.1 24.3 9.9 64 20.2 126 20.5 7599 21.5 6822 22.2 4721 
SCHS Singapore 9978 47.5 43.5 3.5 38 - 0 (c) - 0 (c) 23.1 133 23.1 9857 
SIS USA 15314 46.3 35 4.5 397 - 0 (c) - 0 (c) 23.4 15261 25.8 12844 
SMC Sweden 26110 44.8 38.4 6.7 332 20.1 15622 - 0 (c) 22.8 13572 23.6 15681 
USRTC USA 52682 34.4 22.2 12.2 911 20.6 40519 21.5 27083 22.9 42389 24.4 21376 
WLHS Sweden 47017 39.6 29.2 10.7 662 20.2 44319 22.2 12445 22.9 28834 23.8 17873 
All  758592 40.6 18 9.3 13082 20.8 545740 22.3 192575 23.1 503196 24.0 449969 
Abbreviations: BMI: Body-mass index; BWHS: Black Women’s Health Study; CLUE2: Campaign against Cancer and Heart Disease; CSDLH: Canadian Study of Diet, Lifestyle, and Health; CTS: California 
Teachers Study; E3N: Etude Epidémiologique auprès de femmes de la Mutuelle Générale de l'Education Nationale; EPIC: European Prospective Study into Cancer and Nutrition; GS: Breast Cancer Now 
Generations Study; HUNT2:  Helseundersøkelsen i Nord-Trøndelag; MCC: Melbourne Collaborative Cohort Study; NHS: Nurses’ Health Study; NHS2: Nurses’ Health Study 2; NOWAC: Norwegian Women 
and Cancer Study; NYUWHS: New York University Women’s Health Study; RERF: Radiation Effects Research Foundation Lifespan Study; SCHS: Singapore Chinese Health Study; SIS: Sister Study; 
SMC: Swedish Mammography Cohort; USRT: United States Radiologic Technologist Cohort; SWLHS: Sweden Women’s Lifestyle and Health Study. References for details of each cohort have previously 
been published 1 (a) case-cohort selected from a cohort of 28000 women recruited under age 55 (b) EPIC includes cohorts from 8 European countries (c) Data not collected at these age groups for these 
studies
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eTable 2: Relative risk of premenopausal breast cancer in relation to BMI category, by age at BMI, for all subjects and 
subjects with information on BMI at age 18-24 years.  
 All subjects  Subjects with BMI at age 18-24 years 
  Multivariable-adjusted   Multivariable-adjusted  Multivariable-adjusted 
plus BMI at age 18-24 years  
Age at BMI BMI category, kg/m2 No. of cases HR (95% CI) (a)  No. of cases HR (95% CI) (a)  HR (95% CI) (b) 
         
BMI at age 18-24 years 
 15.0-16.9 328 1.15 (1.03-1.29)  328 1.15 (1.03-1.29)   
 17.0-18.4 1169 1.09 (1.02-1.16)  1169 1.09 (1.02-1.16)   
 18.5-22.9 6364 1.00 (ref)  6364 1.00 (ref)   
 23.0-24.9 864 0.80 (0.75-0.86)  864 0.80 (0.75-0.86)   
 25.0-27.4 418 0.73 (0.66-0.81)  418 0.73 (0.66-0.81)   
 27.5-29.9 141 0.68 (0.58-0.81)  141 0.68 (0.58-0.81)   
 30.0-32.4 81 0.73 (0.58-0.90)  81 0.73 (0.58-0.90)   
 32.5-34.9 25 0.47 (0.32-0.70)  25 0.47 (0.32-0.70)   
 35.0-49.9 15 0.27 (0.16-0.45)  15 0.27 (0.16-0.45)   
 Trend per 5 kg/m2 (c) 7908 0.77 (0.73-0.80)  7908 0.77 (0.73-0.80)   
BMI at age 25-34 years 
 15.0-18.4 221 1.22 (1.06-1.40)  187 1.21 (1.04-1.41)  1.16 (0.99-1.36) 
 18.5-22.9 2222 1.00 (ref)  1963 1.00 (ref)  1.00 (ref) 
 23.0-24.9 607 0.91 (0.83-0.99)  546 0.91 (0.83-1.00)  0.94 (0.86-1.04) 
 25.0-27.4 403 0.82 (0.74-0.91)  364 0.81 (0.72-0.90)  0.87 (0.77-0.97) 
 27.5-29.9 176 0.76 (0.65-0.88)  165 0.77 (0.66-0.91)  0.86 (0.73-1.02) 
 30.0-32.4 101 0.67 (0.54-0.81)  93 0.66 (0.54-0.82)  0.77 (0.62-0.96) 
 32.5-34.9 58 0.63 (0.49-0.82)  56 0.65 (0.50-0.85)  0.79 (0.60-1.04) 
 35.0-37.4 38 0.67 (0.48-0.92)  37 0.68 (0.49-0.95)  0.87 (0.62-1.23) 
 37.5-39.9 24 0.64 (0.42-0.95)  23 0.63 (0.42-0.95)  0.84 (0.55-1.29) 
 40.0-49.9 25 0.49 (0.33-0.74)  24 0.49 (0.33-0.74)  0.72 (0.46-1.11) 
 Trend per 5 kg/m2 (c) 3654 0.85 (0.82-0.89)  3271 0.85 (0.82-0.89)  0.92 (0.88-0.97) 
BMI at age 35-44 years 
 15.0-18.4 318 1.05 (0.94-1.18)  215 1.10 (0.96-1.26)  1.05 (0.92-1.21) 
 18.5-22.9 5340 1.00 (ref)  3845 1.00 (ref)  1.00 (ref) 
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eTable 2: continued  
 All subjects  Subjects with BMI at age 18-24 years 
  Multivariable-adjusted   Multivariable-adjusted  Multivariable-adjusted 
plus BMI at age 18-24 years  
Age at BMI BMI category, kg/m2 No. of cases HR (95% CI) (a)  No. of cases HR (95% CI) (a)  HR (95% CI) (b) 
         
 23.0-24.9 1882 0.91 (0.86-0.96)  1392 0.91 (0.85-0.97)  0.94 (0.88-1.00) 
 25.0-27.4 1264 0.82 (0.77-0.88)  977 0.84 (0.78-0.90)  0.88 (0.82-0.95) 
 27.5-29.9 636 0.81 (0.74-0.88)  498 0.82 (0.75-0.90)  0.89 (0.81-0.98) 
 30.0-32.4 417 0.81 (0.73-0.90)  334 0.82 (0.74-0.92)  0.93 (0.82-1.04) 
 32.5-34.9 214 0.70 (0.61-0.80)  174 0.71 (0.61-0.83)  0.82 (0.70-0.96) 
 35.0-37.4 123 0.63 (0.53-0.75)  111 0.69 (0.57-0.84)  0.83 (0.69-1.01) 
 37.5-39.9 74 0.60 (0.48-0.76)  65 0.64 (0.50-0.82)  0.79 (0.62-1.02) 
 40.0-49.9 81 0.49 (0.39-0.61)  73 0.52 (0.41-0.65)  0.68 (0.53-0.87) 
 Trend per 5 kg/m2 (c) 10031 0.87 (0.85-0.89)  7469 0.88 (0.86-0.90)  0.93 (0.91-0.96) 
BMI at age 45-54 years 
 15.0-18.4 120 1.04 (0.87-1.25)  63 1.12 (0.87-1.44)  1.11 (0.86-1.43) 
 18.5-22.9 2484 1.00 (ref)  1535 1.00 (ref)  1.00 (ref) 
 23.0-24.9 1127 0.94 (0.87-1.01)  788 0.94 (0.87-1.03)  0.96 (0.88-1.05) 
 25.0-27.4 859 0.85 (0.79-0.92)  644 0.87 (0.79-0.95)  0.89 (0.81-0.98) 
 27.5-29.9 430 0.77 (0.69-0.85)  338 0.80 (0.71-0.90)  0.84 (0.74-0.94) 
 30.0-32.4 302 0.80 (0.71-0.90)  234 0.79 (0.69-0.91)  0.85 (0.74-0.98) 
 32.5-34.9 160 0.72 (0.61-0.84)  123 0.69 (0.57-0.83)  0.76 (0.63-0.92) 
 35.0-37.4 112 0.76 (0.63-0.92)  83 0.71 (0.57-0.89)  0.80 (0.63-1.00) 
 37.5-39.9 62 0.66 (0.52-0.86)  54 0.71 (0.54-0.93)  0.81 (0.61-1.07) 
 40.0-49.9 70 0.56 (0.44-0.71)  60 0.57 (0.44-0.74)  0.68 (0.52-0.90) 
 Trend per 5 kg/m2 (c) 5606 0.88 (0.86-0.91)  3859 0.88 (0.85-0.91)  0.91 (0.88-0.95) 
         
Abbreviations: BMI, Body-mass Index; CI, confidence interval; HR, hazard ratio 
(a) HRs adjusted for attained age, cohort, year of birth, age at menarche, age at first birth, number of births, time since last birth and family history of breast cancer  
(b) Additionally adjusted for BMI at age 18-24 years 
(c) Linear trend per 5 unit difference fitted across BMI values from 18.5 to 49.9 kg/m2 
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eTable 3: Relative risk of premenopausal breast cancer in relation to BMI, by age at BMI and invasiveness of breast cancer 
                                           Body-mass index category, kg/m2 
   <18.5  18.5-24.9  25.0-29.9  ≥ 30.0  Trend per 5 kg/m2 BMI (b)  
Age at BMI and 




 HR (95% CI) (a)  HR (95% CI) (a)  HR (95% CI) (a)  HR (95% CI) (a)  HR (95% CI) (a) P trend  
              
BMI at age 18-24 years              
Invasive 7738  1.14 (1.07-1.21)  1.00 (ref)  0.75 (0.68-0.82)  0.55 (0.45-0.68)  0.77 (0.74-0.81) <0.001  
In-situ 1582  1.11 (0.96-1.27)  1.00 (ref)  0.71 (0.57-0.88)  0.61 (0.39-0.93)  0.71 (0.64-0.80) <0.001  
       P int=0.92    P int=0.20   
BMI at age 25-34 years              
Invasive 3109  1.25 (1.07-1.46)  1.00 (ref)  0.88 (0.79-0.97)  0.71 (0.61-0.82)  0.88 (0.84-0.92) <0.001  
In-situ 707  1.23 (0.90-1.68)  1.00 (ref)  0.59 (0.47-0.75)  0.47 (0.33-0.68)  0.76 (0.69-0.85) <0.001  
       P int=0.006    P int=0.02   
BMI at age 35-44 years              
Invasive 8486  0.99 (0.87-1.13)  1.00 (ref)  0.86 (0.82-0.91)  0.74 (0.68-0.80)  0.88 (0.86-0.90) <0.001  
In-situ 1775  1.54 (1.23-1.93)  1.00 (ref)  0.73 (0.64-0.83)  0.62 (0.51-0.74)  0.81 (0.76-0.86) <0.001  
       P int=<0.001    P int=0.01   
BMI at age 45-54 years              
Invasive 4676  1.01 (0.82-1.24)  1.00 (ref)  0.85 (0.79-0.91)  0.74 (0.68-0.82)  0.88 (0.85-0.91) <0.001  
In-situ 1010  1.35 (0.92-1.99)  1.00 (ref)  0.81 (0.69-0.94)  0.75 (0.62-0.91)  0.88 (0.82-0.94) <0.001  
       P int=0.51    P int=0.93   
Abbreviations: BMI, Body-mass Index; CI, confidence interval; HR, hazard ratio 
(a) HRs adjusted for attained age, cohort, year of birth, age at menarche, age at first birth, number of births, time since last birth and family history of breast cancer  
(b) Linear trend per 5 unit difference fitted across BMI values from 18.5 to 49.9 kg/m2
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eTable 4: Characteristics of breast cancer cases, by most recent BMI category prior to diagnosis 
 Most recent body-mass index (kg/m2) (a)  
 <18.5 18.5-24.9 25.0-29.9 30.0-34.9 35 All cases 
 N or 
mean 
% N or 
mean 
% N or 
mean 
% N or 
mean 
% N or 
mean 
%  N or 
mean 
% 
              
Mean interval between age at BMI and diagnosis, 
years 
3.4  3.0  2.4  2.1  2.0   2.8  
Age at diagnosis, years           
 
  
<40 48 14.9 810 9.7 220 7.6 74 7.1 39 7.6  1191 9.1 
40-44 91 28.2 1962 23.6 655 22.8 243 23.3 127 24.9  3078 23.5 
45-49 146 45.2 3995 48.0 1355 47.1 472 45.3 237 46.4  6205 47.4 
50-54 38 11.8 1564 18.8 646 22.5 252 24.2 108 21.1  2608 19.9 
Race/ethnicity              
Caucasian 193 84.6 5350 90.0 1890 82.5 695 76.0 309 66.0  8437 85.7 
Black 13 5.7 337 5.7 323 14.1 192 21.0 141 30.1  1006 10.2 
Asian 18 7.9 168 2.8 39 1.7 9 1.0 1 0.2  235 2.4 
Other 4 1.8 88 1.5 39 1.7 19 2.1 17 3.6  167 1.7 
Not known 95  2388  585  126  43   3237  
Ever had mammography for screening (b)              
No 63 28.0 1442 25.7 379 20.3 119 18.1 57 16.4  2060 23.7 
Yes 162 72.0 4169 74.3 1489 79.7 540 81.9 290 83.6  6650 76.3 
Not known 98  2720  1008  382  164   4372  
Invasiveness              
In situ 70 21.7 1385 16.7 440 15.5 156 15.2 87 17.5  2138 16.5 
Invasive 252 78.3 6904 83.3 2401 84.5 868 84.8 411 82.5  10836 83.5 
Not known 1  42  35  17  13   108  
ER status              
Positive 115 71.4 3532 75.2 1352 74.0 537 73.2 263 72.9  5799 74.6 
Negative 46 28.6 1163 24.8 475 26.0 197 26.8 98 27.1  1979 25.4 
Borderline/not known 162  3636  1049  307  150   5304  
Combined ER and PR status              
ER+PR+ 95 63.3 2744 63.2 1086 63.9 437 63.6 208 61.7  4570 63.3 
ER+PR- 11 7.3 487 11.2 162 9.5 60 8.7 36 10.7  756 10.5 
ER-PR+ 39 26.0 836 19.3 365 21.5 158 23.0 86 25.5  1484 20.6 
ER-PR- 5 3.3 274 6.3 86 5.1 32 4.7 7 2.1  404 5.6 
Unclassified 173  3990  1177  354  174   5868  
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eTable 4:continued 
 Most recent body-mass index (kg/m2) (a)  
 <18.5 18.5-24.9 25.0-29.9 30.0-34.9 35 All cases 
 N or 
mean 
% N or 
mean 
% N or 
mean 
% N or 
mean 
% N or 
mean 
%  N or 
mean 
% 
              
Clinicopathological surrogate definition of intrinsic 
tumor subtype (c) 
             
Luminal A-like 40 25.0 1201 25.8 514 28.4 206 28.2 97 27.2  2058 26.7 
Luminal B-like HER2- 8 5.0 240 5.2 82 4.5 35 4.8 17 4.8  382 5.0 
Luminal B-like HER2+ 14 8.8 287 6.2 131 7.2 62 8.5 22 6.2  516 6.7 
Luminal B-like, unclassified 7 4.4 444 9.5 135 7.5 41 5.6 21 5.9  648 8.4 
HER2-enriched 3 1.9 121 2.6 54 3.0 19 2.6 10 2.8  207 2.7 
Triple-negative 10 6.3 269 5.8 116 6.4 53 7.3 35 9.8  483 6.3 
Unclassified luminal 52 32.5 1644 35.3 584 32.2 228 31.2 113 31.7  2621 34.0 
Unclassified non-luminal 26 16.3 446 9.6 195 10.8 86 11.8 41 11.5  794 10.3 
Unclassified 163  3679  1065  311  155   5373  
              
All cases of breast cancer 323 100.0 8331 100.0 2876 100.0 1041 100.0 511 100.0  13082 100.0 
              
Abbreviations: ER, estrogen-receptor; HER2, Human Epidermal Growth Factor Receptor-2; PR, progesterone-receptor 
(a) Most recently assessed BMI prior to diagnosis 
(b) Most recent mammographic screening status prior to diagnosis 
(c) Luminal A-like:  ER+PR+HER2- 
Luminal B-like, all:  All ER+ and/or PR+ tumors that are not ER+PR+HER2- with subtypes Luminal B-like, HER2-:  ER+PR−HER2- and ER−PR+HER2- and Luminal B-like, HER2+:  [ER+ 
and/or PR+] and HER2+  
Non-luminal, all: ER−PR− regardless of HER2 status with subtypes HER2-enriched: ER−PR−HER2+ and Triple-negative: ER−PR−HER2-  
 
 
Downloaded From:  by Institute of Cancer Research UK, minouk schoemaker on 06/22/2018
©2018 The Premenopausal Breast Cancer Collaborative Group. JAMA Oncology. 
eTable 5: Relative risk of premenopausal breast cancer in relation to BMI category, by age at BMI and estrogen or 
progesterone receptor status of breast cancer 
    Body-mass index category, kg/m2 
   <18.5  18.5-24.9  25.0-29.9  ≥30.0  Trend per 5 kg/m2 (b)  




 HR (95% CI) (a)  HR (95% CI) 
(a) 





BMI age 18-24 years              
Estrogen-receptor              
ER+ 4436  1.15 (1.06-1.25)  1.00 (ref)  0.75 (0.66-0.84)  0.55 (0.43-0.72)  0.76 (0.71-0.81) <0.001  
ER- 1478  1.18 (1.02-1.35)  1.00 (ref)  0.79 (0.65-0.97)  0.45 (0.28-0.72)  0.81 (0.74-0.90) <0.001  
Progesterone-receptor       P int=0.82(c)    P int=0.25(c)   
PR+ 3710  1.12 (1.03-1.23)  1.00 (ref)  0.74 (0.64-0.84)  0.47 (0.35-0.63)  0.74 (0.70-0.80) <0.001  
PR- 1723  1.20 (1.05-1.37)  1.00 (ref)  0.77 (0.63-0.93)  0.58 (0.40-0.86)  0.80 (0.73-0.88) <0.001  
BMI age 25-34 years       P int=0.70(c)    P int=0.21(c)   
Estrogen-receptor              
ER+ 1884  1.37 (1.13-1.65)  1.00 (ref)  0.81 (0.71-0.92)  0.64 (0.53-0.77)  0.85 (0.80-0.90) <0.001  
ER- 613  1.03 (0.70-1.52)  1.00 (ref)  0.89 (0.72-1.10)  0.80 (0.60-1.06)  0.90 (0.83-0.99)   0.025  
Progesterone-receptor       P int=0.24(c)    P int=0.26(c)   
PR+ 1626  1.30 (1.05-1.61)  1.00 (ref)  0.83 (0.72-0.95)  0.58 (0.47-0.71)  0.83 (0.78-0.88) <0.001  
PR- 719  1.25 (0.90-1.75)  1.00 (ref)  0.86 (0.70-1.05)  0.90 (0.70-1.16)  0.94 (0.86-1.02)   0.122  
BMI age 35-44 years       P int=0.06(c)    P int=0.02(c)   
Estrogen-receptor              
ER+ 4904  1.02 (0.86-1.21)  1.00 (ref)  0.83 (0.77-0.90)  0.71 (0.64-0.78)  0.87 (0.84-0.90) <0.001  
ER- 1588  1.06 (0.78-1.43)  1.00 (ref)  0.96 (0.85-1.09)  0.81 (0.68-0.95)  0.92 (0.87-0.97) 0.001  
Progesterone-receptor       P int=0.20(c)    P int=0.07(c)   
PR+ 4213  1.04 (0.87-1.25)  1.00 (ref)  0.84 (0.77-0.91)  0.71 (0.64-0.79)  0.86 (0.83-0.89) <0.001  
PR- 1830  1.05 (0.80-1.39)  1.00 (ref)  0.91 (0.81-1.02)  0.79 (0.68-0.92)  0.91 (0.86-0.95) <0.001  
BMI age 45-54 years       P int=0.52(c)    P int=0.08(c)   
Estrogen-receptor              
ER+ 3016  0.76 (0.56-1.02)  1.00 (ref)  0.86 (0.79-0.94)  0.77 (0.69-0.86)  0.90 (0.86-0.93) <0.001  
ER- 867  1.28 (0.83-1.98)  1.00 (ref)  0.81 (0.69-0.96)  0.75 (0.61-0.91)  0.90 (0.84-0.97)   0.004  
Progesterone-receptor       P int=0.22(c)    P int=0.84(c)   
PR+ 2589  0.83 (0.61-1.13)  1.00 (ref)  0.86 (0.78-0.95)  0.79 (0.70-0.89)  0.91 (0.87-0.95) <0.001  
PR- 1064  1.07 (0.70-1.63)  1.00 (ref)  0.80 (0.69-0.93)  0.71 (0.59-0.86)  0.87 (0.82-0.93) <0.001  
       P int=0.49(c)    P int=0.26(c)   
Abbreviations: BMI, Body-mass Index; CI, confidence interval; ER, estrogen-receptor; HR, hazard ratio; PR, progesterone-receptor 
(a) HRs adjusted for attained age, cohort, year of birth, age at menarche, age at first birth, number of births, time since last birth and family history of breast cancer  
(b) Linear trend per 5 unit difference fitted across BMI values from 18.5 to 49.9 kg/m2 
(c) Tests for heterogeneity in effect by ER or PR status obtained from an Augmentation model.8 
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eTable 6: Relative risk of premenopausal breast cancer per 5 kg/m2 difference in BMI, by age at BMI and other breast cancer risk 
factors  
 
 Age at BMI, years 
 BMI at age 18-24 years  BMI at age 25-34 years  BMI at age 35-44 years  BMI at age 45-54 years 
Variable (a) No. of 
cases 
HR (95% CI) (b)  No. of 
cases 
HR (95% CI) (b)  No. of 
cases 
HR (95% CI) (b)  No. of 
cases 
HR (95% CI) (b) 
            
Adult height, cms            
<160 1378 0.79 (0.71-0.87)  666 0.86 (0.78-0.95)  1881 0.88 (0.84-0.93)  1101 0.88 (0.82-0.94) 
160-169 4378 0.76 (0.71-0.80)  1901 0.85 (0.81-0.90)  5509 0.86 (0.83-0.89)  3156 0.87 (0.84-0.90) 
170 2152 0.79 (0.72-0.85)  1087 0.85 (0.79-0.92)  2641 0.89 (0.85-0.93)  1349 0.92 (0.87-0.97) 
Age at menarche, years  
P int=0.65   P int=0.98   P int=0.46   P int=0.26 
<12 1806 0.78 (0.72-0.84)  846 0.90 (0.84-0.97)  2187 0.88 (0.85-0.92)  1209 0.92 (0.87-0.97) 
12-13 4386 0.77 (0.72-0.81)  2067 0.83 (0.78-0.88)  5461 0.87 (0.84-0.90)  3098 0.87 (0.83-0.90) 
14 1562 0.75 (0.67-0.84)  671 0.84 (0.75-0.94)  2111 0.84 (0.79-0.89)  1180 0.89 (0.83-0.96) 
Ever having had a birth  
P int=0.89   P int=0.17   P int=0.41   P int=0.20 
No 1200 0.72 (0.66-0.79)  638 0.79 (0.73-0.87)  1436 0.84 (0.80-0.89)  698 0.85 (0.79-0.91) 
Yes 6461 0.78 (0.74-0.82)  2823 0.88 (0.84-0.93)  8180 0.88 (0.85-0.90)  4734 0.89 (0.86-0.92) 
Age at first birth, years 
(parous)  
P int=0.16   P int=0.03   P int=0.15   P int=0.18 
<25 2472 0.77 (0.71-0.83)  885 0.89 (0.82-0.96)  3285 0.86 (0.82-0.90)  2040 0.90 (0.86-0.94) 
25-34 3550 0.78 (0.73-0.83)  1758 0.87 (0.82-0.93)  4333 0.88 (0.85-0.92)  2396 0.88 (0.84-0.92) 
35 383 0.81 (0.67-0.97)  161 0.84 (0.68-1.03)  522 0.91 (0.82-1.00)  283 0.93 (0.83-1.05) 
Number of births (parous)  P int=0.89   P int=0.84   P int=0.45   P int=0.63 
1 1160 0.82 (0.74-0.90)  603 0.82 (0.74-0.91)  1504 0.87 (0.82-0.92)  787 0.92 (0.86-0.99) 
2 3061 0.79 (0.74-0.86)  1355 0.90 (0.84-0.97)  3893 0.89 (0.85-0.92)  2152 0.91 (0.87-0.96) 
3 2191 0.72 (0.65-0.79)  816 0.86 (0.78-0.95)  2676 0.86 (0.82-0.90)  1763 0.85 (0.81-0.90) 
Time since last birth, years 
(parous) 
 P int=0.12   P int=0.26   P int=0.63   P int=0.09 
<5 298 0.89 (0.72-1.09)  269 0.89 (0.77-1.04)  281 0.86 (0.75-0.99)  21 1.19 (0.81-1.74) 
5-9 814 0.84 (0.74-0.96)  486 0.86 (0.76-0.96)  1036 0.90 (0.83-0.96)  224 0.88 (0.76-1.02) 
10-14 1431 0.75 (0.68-0.84)  719 0.86 (0.78-0.95)  1868 0.88 (0.84-0.93)  729 0.87 (0.80-0.94) 
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eTable 6: continued 
 Age at BMI, years 
 BMI at age 18-24 years  BMI at age 25-34 years  BMI at age 35-44 years  BMI at age 45-54 years 
Variable (a) No. of 
cases 
HR (95% CI) (b)  No. of 
cases 
HR (95% CI) (b)  No. of 
cases 
HR (95% CI) (b)  No. of 
cases 
HR (95% CI) (b) 
            
15-19 1715 0.76 (0.69-0.84)  662 0.87 (0.79-0.96)  2307 0.87 (0.83-0.92)  1446 0.89 (0.84-0.94) 
20 1691 0.77 (0.70-0.85)  499 0.91 (0.81-1.01)  2231 0.86 (0.81-0.90)  2131 0.90 (0.86-0.95) 
Ever used oral 
contraception 
 P int=0.66  P int=0.99  P int=0.85  P int=0.43 
No 1267 0.68 (0.61-0.76)  384 0.85 (0.75-0.97)  2026 0.81 (0.77-0.86)  2044 0.85 (0.81-0.90) 
Yes 6045 0.79 (0.75-0.83)  2979 0.86 (0.82-0.90)  7161 0.88 (0.86-0.91)  3319 0.90 (0.87-0.94) 
Ever diagnosis with 
infertility 
 P int=0.02   P int=0.84   P int=0.009   P int=0.08 
No 3525 0.78 (0.73-0.83)  1767 0.84 (0.79-0.90)  4220 0.89 (0.86-0.92)  1752 0.92 (0.88-0.96) 
Yes 813 0.74 (0.65-0.85)  415 0.86 (0.76-0.96)  1089 0.85 (0.80-0.91)  573 0.90 (0.83-0.98) 
Ever diagnosis with PCOS 
 P int=0.52   P int=0.82   P int=0.30   P int=0.63 
No 1015 0.78 (0.69-0.90)  417 0.81 (0.71-0.94)  1253 0.88 (0.82-0.94)  561 0.92 (0.84-1.01) 
Yes 217 0.67 (0.53-0.86)  110 0.72 (0.58-0.91)  262 0.78 (0.69-0.89)  143 0.84 (0.73-0.98) 
Ever had a mammogram 
 P int=0.28   P int=0.39   P int=0.12   P int=0.30 
No 1322 0.84 (0.75-0.93)  647 0.91 (0.83-1.00)  1389 0.89 (0.83-0.95)  421 0.91 (0.81-1.02) 
Yes 3706 0.76 (0.71-0.81)  1378 0.83 (0.77-0.88)  5393 0.87 (0.84-0.89)  3549 0.88 (0.85-0.92) 
Family history of breast 
cancer 
 P int=0.12   P int=0.08   P int=0.52   P int=0.67 
No  5889 0.75 (0.72-0.79)  2749 0.86 (0.82-0.90)  6800 0.87 (0.84-0.89)  3814 0.88 (0.85-0.91) 
Yes 1610 0.80 (0.73-0.87)  768 0.83 (0.75-0.91)  2312 0.89 (0.85-0.93)  1446 0.90 (0.86-0.95) 
Attained education level 
 P int=0.32   P int=0.45   P int=0.34   P int=0.41 
Primary and lower 325 0.84 (0.66-1.05)  35 0.90 (0.61-1.32)  318 0.76 (0.64-0.89)  226 0.82 (0.68-0.99) 
High School 485 0.80 (0.67-0.96)  204 0.84 (0.72-0.99)  522 0.88 (0.80-0.97)  203 0.84 (0.72-0.98) 
Some college education 1320 0.81 (0.73-0.90)  831 0.89 (0.82-0.96)  1687 0.86 (0.82-0.91)  563 0.90 (0.83-0.98) 
University 4821 0.75 (0.71-0.79)  2288 0.85 (0.80-0.90)  5502 0.88 (0.85-0.91)  3343 0.88 (0.85-0.92) 
  
P int=0.51  P int=0.82  P int=0.30  P int=0.72 
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eTable 6: continued 
 Age at BMI, years 
 BMI at age 18-24 years  BMI at age 25-34 years  BMI at age 35-44 years  BMI at age 45-54 years 
Variable (a) No. of 
cases 
HR (95% CI) (b)  No. of 
cases 
HR (95% CI) (b)  No. of 
cases 
HR (95% CI) (b)  No. of 
cases 
HR (95% CI) (b) 
Ethnicity            
Caucasian 5922 0.73 (0.70-0.77)  2836 0.83 (0.79-0.88)  6708 0.86 (0.84-0.89)  3780 0.88 (0.85-0.91) 
Black 709 0.84 (0.76-0.93)  460 0.90 (0.83-0.98)  820 0.90 (0.85-0.95)  282 0.91 (0.83-1.01) 
Asian 79 0.69 (0.40-1.18)  93 0.89 (0.61-1.31)  124 1.02 (0.77-1.36)  90 0.80 (0.57-1.12) 
Continent  P int=0.08   P int=0.29   P int=0.30   P int=0.68 
North-America 5603 0.76 (0.72-0.80)  2960 0.86 (0.82-0.90)  6669 0.88 (0.86-0.90)  3658 0.89 (0.86-0.92) 
Europe 2236 0.80 (0.73-0.88)  657 0.81 (0.72-0.90)  3279 0.84 (0.80-0.89)  1857 0.85 (0.79-0.91) 
Asia    37 1.79 (0.95-3.40)  38 0.75 (0.39-1.44)  37 0.71 (0.39-1.28) 
Australia 69 0.65 (0.38-1.12)  2960 0.86 (0.82-0.90)  45 0.68 (0.45-1.02)  54 1.06 (0.79-1.40) 
Year of birth  
P int=0.48   P int=0.07   P int=0.25   P int=0.33 
<1940 976 0.75 (0.66-0.85)  22 1.55 (0.66-3.66)  1012 0.85 (0.78-0.92)  1083 0.84 (0.78-0.91) 
1940-1949 1770 0.72 (0.65-0.79)  777 0.83 (0.74-0.92)  2912 0.83 (0.79-0.88)  2410 0.86 (0.82-0.90) 
1950-1959 3623 0.78 (0.73-0.83)  1461 0.86 (0.80-0.92)  4563 0.88 (0.85-0.91)  1703 0.90 (0.86-0.95) 
1960 1539 0.80 (0.73-0.87)  1394 0.85 (0.80-0.91)  1544 0.90 (0.85-0.94)  410 0.94 (0.87-1.03) 
  
P int=0.41   P int=0.58   P int=0.20   P int=0.11 
Abbreviations: BMI, Body-mass Index; CI, confidence interval; HR, hazard ratio; PCOS, polycystic ovary syndrome 
(a) Stratifying variables are time-updated, where possible, for reproductive variables, oral contraceptive use, infertility, PCOS, screening mammogram and family history of breast cancer.  
(b) Hazard ratio represents linear trend per 5 kg/m2 difference fitted across BMI values from 18.5 to 49.9 kg/m2 and are adjusted for attained age, cohort, year of birth, age at menarche, age 
at first birth, number of births, time since last birth and family history of breast cancer.   
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eTable 7:  Relative risk of premenopausal breast cancer in relation to BMI category, by age at BMI. For (1) all subjects included in 
main analysis (2) breast cancer with known ER, PR and HER2 status as endpoint (3) excluding subjects with weight assessed less 






on on all 



















































































                






































































































































 25.0 4 0.73  1 0.71  3 0.73  2 0.75  3 0.73 













































































































































































































































































































































































 32.5 5 0.63  2 0.70  3 0.61  2 0.65  5 0.64 


























































































eTable 7:  continued 
 All subjects  Cases with 
information 
on all of 




















first two  
years of 
follow-up 
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 61 0.57 
(0.45-
0.74) 








 20 0.53 
(0.34-
0.82) 
 63 0.59 
(0.46-
0.76) 
 31 0.49 
(0.34-
0.70) 








 20 0.39 
(0.25-
0.60) 
 73 0.50 
(0.39-
0.63) 
 36 0.43 
(0.31-
0.59) 
















































































































































































 260 0.81 
(0.71-
0.92) 








































 86 0.77 
(0.62-
0.96) 








 21 0.56 
(0.36-
0.86) 
 62 0.67 
(0.52-
0.87) 
 42 0.60 
(0.44-
0.82) 








 33 0.65 
(0.46-
0.92) 
 69 0.55 
(0.43-
0.71) 
 48 0.52 
(0.39-
0.69) 
 61 0.54 
(0.42-
0.70) 
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Abbreviations: BMI, Body-mass Index; HR, hazard ratio;  CI, confidence interval; HER2, human epidermal growth factor receptor-2; ER, estrogen-receptor;  PR, progesterone-receptor 
(a) HRs adjusted for attained age, cohort, year of birth, age at menarche, age at first birth, number of births, time since last birth and family history of breast cancer  
(b) Linear trend per 5 unit difference fitted across BMI values from 18.5 to 49.9 kg/m2
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eTable 8:  Relative risk of premenopausal breast cancer in relation to BMI category at age 18-24 years, excluding subjects 
contributing to each successive cohort. 
     Body-mass index category, kg/m2 
 







 HR (95% CI)(a) HR (95% CI)  HR (95% CI)(a)  HR (95% CI)(a)  HR (95% CI)(a)  HR (95% CI)(a) P trend  
               
No exclusions 9405  1.13 (1.07-1.20) 1.00 (ref)  0.74 (0.68-0.81)  0.66 (0.55-0.81)  0.28 (0.17-0.47)  0.77 (0.73-0.80) <0.001  
               
BWHS 8585  1.11 (1.05-1.18) 1.00 (ref)  0.76 (0.69-0.83)  0.64 (0.51-0.79)  0.23 (0.12-0.44)  0.75 (0.72-0.79) <0.001  
CLUE2 9341  1.13 (1.07-1.20) 1.00 (ref)  0.74 (0.68-0.81)  0.67 (0.56-0.82)  0.29 (0.17-0.47)  0.77 (0.73-0.80) <0.001  
CSDLH 9192  1.14 (1.07-1.20) 1.00 (ref)  0.74 (0.68-0.81)  0.66 (0.54-0.80)  0.28 (0.17-0.47)  0.77 (0.73-0.80) <0.001  
CTS 8769  1.13 (1.07-1.20) 1.00 (ref)  0.74 (0.68-0.81)  0.67 (0.55-0.82)  0.30 (0.17-0.50)  0.77 (0.74-0.81) <0.001  
E3N (c) -  - -  -  -  -  - -  
EPIC 8993  1.14 (1.08-1.21) 1.00 (ref)  0.74 (0.68-0.81)  0.66 (0.54-0.80)  0.29 (0.17-0.48)  0.76 (0.73-0.80) <0.001  
GS 8764  1.13 (1.07-1.20) 1.00 (ref)  0.73 (0.67-0.80)  0.65 (0.53-0.80)  0.30 (0.18-0.49)  0.76 (0.73-0.80) <0.001  
HUNT2 (d) -  - -  -  -  -  - -  
MCC 9322  1.13 (1.07-1.20) 1.00 (ref)  0.74 (0.68-0.81)  0.67 (0.55-0.81)  0.28 (0.17-0.47)  0.77 (0.73-0.80) <0.001  
NHS 7428  1.12 (1.05-1.19) 1.00 (ref)  0.76 (0.69-0.84)  0.65 (0.53-0.81)  0.26 (0.15-0.45)  0.79 (0.75-0.83) <0.001  
NHS2 6912  1.14 (1.07-1.22) 1.00 (ref)  0.72 (0.65-0.80)  0.71 (0.57-0.89)  0.30 (0.17-0.55)  0.76 (0.72-0.80) <0.001  
NOWAC 8638  1.14 (1.08-1.21) 1.00 (ref)  0.73 (0.67-0.80)  0.65 (0.53-0.79)  0.29 (0.17-0.48)  0.76 (0.73-0.80) <0.001  
NYUWHS (c) -  - -  -  -  -  - -  
RERF (d) -  - -  -  -  -  - -  
SCHS (c) -  - -  -  -  -  - -  
SIS (c) -  - -  -  -  -  - -  
SMC 9195  1.14 (1.07-1.20) 1.00 (ref)  0.74 (0.68-0.81)  0.66 (0.55-0.80)  0.28 (0.17-0.47)  0.76 (0.73-0.80) <0.001  
USRTC 8948  1.13 (1.07-1.20) 1.00 (ref)  0.74 (0.68-0.81)  0.69 (0.56-0.83)  0.28 (0.16-0.47)  0.77 (0.73-0.80) <0.001  
WLHS 8773  1.13 (1.07-1.20) 1.00 (ref)  0.74 (0.68-0.81)  0.67 (0.56-0.82)  0.29 (0.17-0.48)  0.77 (0.73-0.80) <0.001  
               
Abbreviations: BMI, Body-mass Index; CI, confidence interval; HR, hazard ratio; for cohort abbreviations see page 3. 
 (a) HRs adjusted for attained age, cohort, year of birth, age at menarche, age at first birth, number of births, time since last birth and family history of breast cancer 
(b) Linear trend per 5 unit difference fitted across BMI values from 18.5 to 49.9 kg/m2 
(c) BMI data at age 18-24 years not collected for these cohorts  
(d) Insufficient number of cases with BMI at age 18-24 years for these cohorts
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eTable 9:  Relative risk of premenopausal breast cancer in relation to BMI category at age 45-54 years, excluding subjects 
contributing to each successive cohort. 
Abbreviations: BMI, Body-mass Index; CI, confidence interval; HR, hazard ratio; for cohort abbreviations see page 3. 
(a) HRs adjusted for attained age, cohort, year of birth, age at menarche, age at first birth, number of births, time since last birth and family history of breast cancer 
(b) Linear trend per 5 unit difference fitted across BMI values from 18.5 to 49.9 kg/m2 
(c) Insufficient number of cases with BMI at age 45-54 years for this cohort 
     Body-mass index category, kg/m2 
 





 HR (95% CI) (a)  HR (95% CI)   HR (95% CI) (a)  HR (95% CI) (a)  HR (95% CI) (a)  HR (95% CI)(a) P 
trend 
 
                
No exclusions 5726  1.06 (0.88-1.27)  1.00 (ref)  0.84 (0.79-0.90)  0.79 (0.71-0.87)  0.68 (0.60-0.78)  0.88 (0.86-0.91) <0.001  
                
BWHS 5515  1.06 (0.89-1.28)  1.00 (ref)  0.85 (0.80-0.91)  0.78 (0.70-0.87)  0.69 (0.60-0.80)  0.88 (0.86-0.91) <0.001  
CLUE2 5704  1.06 (0.89-1.28)  1.00 (ref)  0.84 (0.79-0.90)  0.78 (0.71-0.86)  0.69 (0.60-0.79)  0.88 (0.86-0.91) <0.001  
CSDLH 5707  1.06 (0.88-1.27)  1.00 (ref)  0.85 (0.79-0.90)  0.78 (0.71-0.87)  0.68 (0.60-0.78)  0.88 (0.86-0.91) <0.001  
CTS 5593  1.07 (0.89-1.29)  1.00 (ref)  0.84 (0.79-0.90)  0.78 (0.70-0.86)  0.68 (0.60-0.78)  0.88 (0.85-0.91) <0.001  
E3N 4719  1.03 (0.82-1.30)  1.00 (ref)  0.84 (0.78-0.90)  0.79 (0.71-0.87)  0.67 (0.59-0.77)  0.88 (0.85-0.91) <0.001  
EPIC 5596  1.08 (0.90-1.29)  1.00 (ref)  0.84 (0.79-0.90)  0.79 (0.71-0.87)  0.68 (0.59-0.78)  0.89 (0.86-0.91) <0.001  
GS 5481  1.06 (0.89-1.28)  1.00 (ref)  0.84 (0.78-0.90)  0.78 (0.71-0.87)  0.68 (0.59-0.77)  0.88 (0.85-0.91) <0.001  
HUNT2 5707  1.06 (0.89-1.28)  1.00 (ref)  0.85 (0.79-0.90)  0.78 (0.71-0.87)  0.68 (0.60-0.78)  0.88 (0.86-0.91) <0.001  
MCC 5672  1.07 (0.89-1.28)  1.00 (ref)  0.84 (0.79-0.90)  0.78 (0.71-0.87)  0.68 (0.59-0.77)  0.88 (0.85-0.91) <0.001  
NHS 4159  1.04 (0.85-1.29)  1.00 (ref)  0.86 (0.80-0.93)  0.83 (0.74-0.93)  0.71 (0.61-0.83)  0.90 (0.87-0.93) <0.001  
NHS2 4431  1.02 (0.84-1.25)  1.00 (ref)  0.82 (0.77-0.89)  0.78 (0.69-0.88)  0.66 (0.56-0.78)  0.87 (0.84-0.90) <0.001  
NOWAC 5494  1.07 (0.89-1.28)  1.00 (ref)  0.84 (0.78-0.90)  0.79 (0.72-0.87)  0.68 (0.60-0.78)  0.88 (0.86-0.91) <0.001  
NYUWHS  5619  1.06 (0.88-1.27)  1.00 (ref)  0.85 (0.79-0.91)  0.78 (0.71-0.87)  0.69 (0.61-0.79)  0.89 (0.86-0.91) <0.001  
RERF (c) -  -  -  -  -  -  - -  
SCHS 5689  1.08 (0.90-1.30)  1.00 (ref)  0.85 (0.79-0.90)  0.79 (0.71-0.87)  0.68 (0.60-0.78)  0.88 (0.86-0.91) <0.001  
SIS 5458  1.08 (0.89-1.29)  1.00 (ref)  0.84 (0.79-0.90)  0.77 (0.69-0.85)  0.68 (0.59-0.78)  0.88 (0.85-0.91) <0.001  
SMC 5582  1.06 (0.89-1.28)  1.00 (ref)  0.85 (0.80-0.91)  0.79 (0.71-0.87)  0.69 (0.60-0.79)  0.89 (0.86-0.91) <0.001  
USRTC 5627  1.03 (0.86-1.25)  1.00 (ref)  0.83 (0.78-0.89)  0.78 (0.71-0.86)  0.68 (0.59-0.77)  0.88 (0.85-0.91) <0.001  
WLHS 5589  1.07 (0.89-1.29)  1.00 (ref)  0.85 (0.79-0.90)  0.79 (0.71-0.87)  0.68 (0.59-0.78)  0.88 (0.86-0.91) <0.001  
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eFigure 1: Relative risk of premenopausal breast cancer in relation to BMI relative to 
the reference category of 20 kg/m2, by age at BMI 
 
Abbreviations: BMI, Body-mass Index; HR, hazard ratio 
 
HRs obtained from 5-knot restricted cubic spline model adjusted for attained age, cohort, year of birth, age at menarche, age at first birth, 
number of births, time since last birth and family history of breast cancer. Knot locations are based on Harrell’s recommended 
percentiles5 as specified in Stata4, corresponding to the 5th, 25th, 50th, 75% and 95% percentile distribution. Solid line represents hazard 
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eFigure 2: Relative risk of premenopausal breast cancer in relation to BMI at ages 
18-24 years relative to the reference category of 20 kg/m2, by combined ER/PR status 
of breast cancer 
 
Abbreviations: BMI, Body-mass Index; ER, estrogen-receptor; HR, hazard ratio; PR, progesterone-receptor 
 
HRs obtained from 5-knot restricted cubic spline model adjusted for attained age, cohort, year of birth, age at menarche, age at first birth, 
number of births, time since last birth and family history of breast cancer. Knot locations are based on Harrell’s recommended 
percentiles5 as specified in Stata4, corresponding to the 5th, 25th, 50th, 75% and 95% percentile distribution. Solid line represents hazard 
ratio relative to the reference group of 20 kg/m2, dashed line represents 95% confidence interval of hazard ratio. Note the different Y-axis 
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eFigure 3a: Forest plot of study-specific hazard ratios of premenopausal 
breast cancer by BMI category, relative to BMI 18.5-24.9 kg/m2, at age 18-
24 years. 
 
Abbreviations: BMI, Body-mass Index; CI, confidence interval; HR, hazard ratio; for cohort abbreviations see eMethods. 
aHRs adjusted for attained age, year of birth, age at menarche, age at first birth, number of births, time since last birth and 
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eFigure 3b: Forest plot of study-specific hazard ratios of premenopausal 
breast cancer by BMI category, relative to BMI 18.5-24.9 kg/m2, at age 25-34 
years. 
 
Abbreviations: BMI, Body-mass Index; CI, confidence interval; HR, hazard ratio; for cohort abbreviations see eMethods. 
aHRs adjusted for attained age, year of birth, age at menarche, age at first birth, number of births, time since last birth and 
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eFigure 3c: Forest plot of study-specific hazard ratios of premenopausal 
breast cancer by BMI category, relative to BMI 18.5-24.9 kg/m2, at age 35-44 
years. 
 
Abbreviations: BMI, Body-mass Index; CI, confidence interval; HR, hazard ratio; for cohort abbreviations see eMethods. 
aHRs adjusted for attained age, year of birth, age at menarche, age at first birth, number of births, time since last birth and 
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eFigure 3d: Forest plot of study-specific hazard ratios of premenopausal 
breast cancer by BMI category, relative to BMI 18.5-24.9 kg/m2, at age 45-54 
years. 
 
Abbreviations: BMI, Body-mass Index; CI, confidence interval; HR, hazard ratio; for cohort abbreviations see eMethods. 
aHRs adjusted for attained age, year of birth, age at menarche, age at first birth, number of births, time since last birth and family 
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eFigure 4: Relative risk of premenopausal breast cancer per 5 kg/m2 difference in 
BMI, by age at BMI and attained age during follow-up 
 
Abbreviations: BMI, body-mass index; CI, confidence interval; HR, hazard ratio; Pint=p value for interaction 
aHRs represent linear trend per 5 kg/m2 difference in BMI from 18.5 to 49.9 kg/m2 and are adjusted for attained age, cohort and year of 
birth, age at menarche, age at first birth, number of births, time since last birth and family history of breast cancer
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eFigure 5: Relative risk of premenopausal breast cancer per 5 kg/m2 difference in 
BMI, by age at BMI and combined estrogen and progesterone receptor status of 
breast cancer 
 
Abbreviations: BMI, body-mass index; CI, confidence interval; ER, estrogen-receptor; HR, hazard ratio; PR, progesterone-
receptor; Pint=p value for interaction 
aHRs represent linear trend per 5 kg/m2 difference in BMI from 18.5 to 49.9 kg/m2 and are adjusted for attained age, cohort, 
year of birth, age at menarche, age at first birth, number of births, time since last birth and family history of breast cancer. 
Tests for heterogeneity in effect by combined ER/PR status was obtained from an Augmentation model including all four 
endpoints.8
BMI at age 18-24 years
BMI at age 25-34 years
BMI at age 35-44 years



























































  0.5 1.0 2.0
HRa 95% CI
Downloaded From:  by Institute of Cancer Research UK, minouk schoemaker on 06/22/2018
©2018 The Premenopausal Breast Cancer Collaborative Group. JAMA Oncology. 
eFigure 6: Relative risk of premenopausal breast cancer per 5 kg/m2 
difference in BMI at age 18-24 years, by selected other breast cancer risk 
factors 
 
Abbreviations: BMI, body-mass index; CI, confidence interval; HR, hazard ratio; PCOS, polycystic ovary syndrome; Pint=p value for 
interaction 
aHRs represent linear trend per 5 kg/m2 difference in BMI from 18.5 to 49.9 kg/m2. HRs adjusted for attained age, cohort, year of birth, 
age at menarche, age at first birth, number of births, time since last birth and family history of breast cancer. Stratifying risk factors are 
time-updated, where data from follow-up questionnaires have been provided.   
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